Simon Hughes

Guy's and St Thomas' NHS Foundation Trust — United Kingdom

Medicine · Health Sciences

23h-index2.3kcitations112works1.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(29), Prostate Cancer Diagnosis and Treatment(22), Bladder and Urothelial Cancer Treatments(21), Advanced Radiotherapy Techniques(13), Urinary and Genital Oncology Studies(12)

Publications111 total

ACE-RT, A Cloud-Based Tool for Remote Radiotherapy Contouring Support in Lower-Resourced Settings: A Pilot Evaluation
Clinical Oncology·2025Open Access
LBA86 Randomised phase III trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)
Annals of Oncology·2025· 1 cited
2535eP Incidence of incidental primary lung malignancies vs. solitary prostate cancer lung metastasis detected on PSMA-PET CT scans for prostate cancer staging and surveillance
Annals of Oncology·2025
3205eP Analysis of X posts during ESMO 2024 by Medical Watch
Annals of Oncology·2025
Artificial intelligence‐driven streamlining of prostate cancer multidisciplinary team recommendations in a tertiary <scp>NHS</scp> centre in the UK
British Journal of Urology·2025· 2 cited
537 Planning feasibility study for HDR-brachytherapy to treat muscle invasive bladder cancer
Radiotherapy and Oncology·2025
Treatment preferences of patients with muscle invasive bladder cancer: A discrete choice experiment
BJUI Compass·2024· 7 citedOpen Access
Indian consensus statements on the management of small renal masses, non‐muscle invasive bladder cancer and high‐risk/locally advanced prostate cancer
BJUI Compass·2024Open Access
1451: Developing a cloud-based tool to improve radiotherapy contouring training in low-resourced settings
Radiotherapy and Oncology·2024
Text-message reminders to increase participation in colorectal cancer screening
British Journal of General Practice·2024· 1 citedOpen Access
Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP1303) and DASL-HiCaP (ANZUP1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa).
Journal of Clinical Oncology·2024· 2 cited
A cohort profile of the Graham Roberts study cohort
Frontiers in Oncology·2024Open Access
Impact of prostate radiotherapy on survival outcomes in clinically node-positive prostate cancer: A multicentre retrospective analysis
Radiotherapy and Oncology·2023· 2 cited
DASL-HiCaP: A randomized, phase 3, double-blind trial of darolutamide with androgen-deprivation therapy and definitive or salvage radiation for localized very high-risk prostate cancer.
Journal of Clinical Oncology·2023· 1 cited
DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.
Journal of Clinical Oncology·2022· 2 cited
DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.
Journal of Clinical Oncology·2022· 1 cited
MP50-15 QUANTIFYING THE PROBABILITY OF NEEDING SALVAGE RADIOTHERAPY FOLLOWING ROBOTIC PROSTATECTOMY: STRATIFICATION USING PROSPECTIVE CLINICAL, RADIOLOGICAL AND PATHOLOGICAL DATA
The Journal of Urology·2021
DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.
Journal of Clinical Oncology·2021
Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer
International Journal of Radiation Oncology*Biology*Physics·2020· 40 citedOpen Access
Cohort profile: King’s Health Partners bladder cancer biobank
BMC Cancer·2020Open Access
page 1 of 6Next →

Frequent Co-authors

David Landau(9), Simon Chowdhury(7), Jamie R. McClelland(7), Paul J. Ross(6), S Tarte(6), David J. Hawkes(6), Mieke Van Hemelrijck(6), Deborah Enting(6), Tania Kalsi(5), G. Babic-Illman(5), N. Maisey(5), Paul Fields(5), Yanzhong Wang(5), Danielle Harari(5), Heather Payne(5), Muhammad Shamim Khan(5), S. Ahmad(5), Sarah Rudman(4), Rajesh Nair(4), Thomas Powles(3)